DEXA Bone Density: Sex- and Cycle-Related Differences, Normal Ranges, and Optimal Targets

What the DEXA Report Actually Measures

A DEXA scan fires two low-energy X-ray beams at target skeletal sites, most commonly the lumbar spine (L1-L4), total hip, and femoral neck, and calculates the bone mineral density (BMD) in grams per square centimeter (g/cm²). The machine then converts that raw number into two normalized scores.

The T-score compares your BMD to the mean BMD of a healthy 30-year-old of the same sex. The Z-score compares it to age- and sex-matched peers. The World Health Organization's 1994 diagnostic criteria, still in routine clinical use, define normal as a T-score at or above -1.0, osteopenia as -1.0 to -2.5, and osteoporosis as -2.5 or below (WHO Study Group, 1994).

T-Score vs. Z-Score: When Each Matters

T-scores drive fracture-risk decisions in postmenopausal women and men aged 50 and older. Z-scores are preferred for premenopausal women, men under 50, and children, because comparing a 32-year-old's BMD against a 30-year-old reference population would pathologize normal variation. The International Society for Clinical Densitometry (ISCD) specifies that a Z-score at or below -2.0 in a premenopausal woman should be labeled "below the expected range for age" rather than osteoporosis, triggering a secondary-cause workup (ISCD 2019 Official Positions).

Precision, Least Significant Change, and Scan Intervals

DEXA has a precision error of roughly 1-2% at the lumbar spine and 2-3% at the femoral neck. The least significant change (LSC) is approximately 3-5%, meaning two sequential scans must differ by at least that margin before a real biologic change can be inferred. Repeat scanning more frequently than every 1-2 years in stable patients adds radiation exposure without improving clinical decisions (ISCD 2019 Official Positions).

Normal Ranges and Optimal Targets by Site

WHO Classification at a Glance

| Classification | T-score Range | |---|---| | Normal | -1.0 and above | | Osteopenia (low bone mass) | -1.0 to -2.5 | | Osteoporosis | -2.5 and below | | Severe osteoporosis | -2.5 and below with a fragility fracture |

The "normal" cut-off of -1.0 was chosen statistically, not physiologically. A large longitudinal analysis published in the Journal of Bone and Mineral Research found that each standard deviation decrease in femoral neck BMD increased hip fracture risk approximately 2.6-fold, confirming that the continuous relationship between BMD and fracture risk begins well above the -2.5 threshold (Marshall et al., JBMR 1996).

What "Optimal" Means in Longevity Medicine

In standard clinical practice, a T-score of -1.0 is the floor of normal. In longevity-oriented practice, the target shifts higher. Published data from the Study of Osteoporotic Fractures (SOF, N=9,704 women) show that fracture incidence curves are essentially flat from T-score +1.0 down to approximately -0.5, then begin rising measurably in the -0.5 to -1.0 band before accelerating sharply below -1.0 (Cummings et al., NEJM 1993). A practical longevity target is a lumbar spine T-score of -0.5 or better and a total hip T-score of -0.5 or better for both sexes. Femoral neck T-score is the single site used for WHO classification per ISCD guidance, but the lumbar spine often detects early loss first, particularly in perimenopausal women, because trabecular bone turns over faster than cortical bone.

Sex Differences in Bone Mineral Density

Men and women accumulate bone differently from childhood onward, reach different peak values, and lose bone through distinct hormonal mechanisms.

Peak Bone Mass: Why Men Start Higher

Men achieve approximately 10% greater bone mass at the hip and spine than women, largely because androgens drive periosteal apposition (outward bone expansion), producing bones with a larger cross-sectional diameter. This geometric advantage persists even when volumetric BMD is similar between sexes (Seeman, JBMR 2003). Testosterone also acts on bone partly by aromatizing to estradiol, so estrogen signaling in bone is active in both sexes, not only women.

Peak bone mass is reached between ages 25 and 30 in both sexes, with women reaching it slightly earlier (around age 25) and men slightly later (around age 28-30). Roughly 60-80% of peak bone mass is determined by genetics; the remainder reflects nutrition, mechanical loading, and hormonal status during adolescence (Bonjour et al., Osteoporos Int 2009).

Age-Related Loss in Men

Men lose bone at a rate of roughly 0.5-1.0% per year after age 50, accelerating slightly as bioavailable testosterone and estradiol decline with age. There is no male equivalent of menopause-related rapid bone loss; instead, the trajectory is gradual. The European Male Ageing Study found that estradiol below 62 pmol/L was a stronger predictor of low BMD in older men than testosterone below 11 nmol/L (Khosla et al., JCEM 2008). This finding supports measuring estradiol, not only testosterone, when evaluating bone health in men.

Estrogen Dominance in Female Bone Regulation

In women, estrogen suppresses osteoclast activity and reduces bone resorption. Estrogen receptor-alpha on osteoclast precursors signals apoptosis when occupied; when estrogen falls, those cells survive longer and resorb more bone. Serum estradiol below 40 pg/mL is associated with measurably higher bone turnover markers in women across the age spectrum (Garnero et al., JCEM 1996).

How the Menstrual Cycle Affects Bone Density

The menstrual cycle creates a monthly rhythm of estrogen and progesterone that has measurable effects on short-term bone marker fluctuations, though its effect on long-term DEXA measurements is subtler than the effects of amenorrhea.

Bone Turnover Markers Across the Cycle

Serum C-terminal telopeptide of type I collagen (CTX), a resorption marker, falls during the mid-cycle estrogen peak and rises in the low-estrogen early follicular phase. Procollagen type I N-terminal propeptide (P1NP), a formation marker, shows a complementary but smaller oscillation. A cross-sectional study of 97 eumenorrheic women aged 20-35 documented a 15-20% within-cycle variation in CTX, sufficient to confound interpretation of single-point bone turnover testing if the cycle phase is not recorded (Schlemmer and Hassager, Clin Endocrinol 1999). For this reason, bone turnover markers should be drawn in the mid-luteal phase (days 18-24) or consistently at the same cycle phase for serial comparison.

DEXA Itself Is Not Cycle-Phase Sensitive

DEXA BMD values do not change meaningfully across a single menstrual cycle. The precision error of the scan (1-2% at the lumbar spine) is larger than any within-cycle BMD fluctuation. Clinically, there is no need to schedule a DEXA scan at a specific cycle phase, but cycle phase should be documented alongside any bone turnover marker draw.

Amenorrhea and Bone Loss

The cycle-related effects matter most when the cycle stops. Functional hypothalamic amenorrhea (FHA), seen in athletes, women with low body weight, and those under severe caloric restriction, produces prolonged hypoestrogenism that can cause bone loss of 2-3% per year at the lumbar spine (Gordon et al., Pediatrics 2017). The Female Athlete Triad and its updated construct, Relative Energy Deficiency in Sport (RED-S), both identify low BMD as a primary outcome of energy deficit-driven estrogen suppression. DEXA is the recommended screening tool when FHA lasts more than 6 months (American College of Sports Medicine, Med Sci Sports Exerc 2007).

Perimenopausal and Postmenopausal Bone Loss

The transition from the final menstrual period to 5 years postmenopause is the highest-velocity bone loss window in a woman's life.

The Acceleration Window

Longitudinal data from the Study of Women's Health Across the Nation (SWAN, N=2,311) show that women lose an average of 10.6% of lumbar spine BMD and 9.1% of total hip BMD in the 6 years spanning the final menstrual period (3 years before to 3 years after) (Greendale et al., JBMR 2012). The greatest annual loss rate, up to 3-5% per year, occurs in the first 2 years after the final menstrual period. Women who enter menopause with lower baseline BMD or with prior low-estrogen intervals (such as FHA or postpartum lactation) may reach the osteoporotic threshold earlier than expected.

Lactation and Transient Bone Loss

Lactation suppresses estrogen via elevated prolactin and reduced GnRH pulsatility, producing a reversible bone loss of 3-5% at the lumbar spine over 6 months of exclusive breastfeeding (Kalkwarf and Specker, Am J Clin Nutr 1995). This loss is typically recovered within 6-12 months after weaning. DEXA during active lactation will underestimate a woman's true baseline BMD.

Postmenopausal Loss Slows but Does Not Stop

After the initial rapid-loss window, bone loss settles to approximately 1-1.5% per year at the hip and 1-2% per year at the spine through the 60s and 70s. By age 80, women have lost an average of 30-40% of their peak lumbar spine BMD (Riggs et al., JBMR 2008). Men at the same age have lost roughly 15-20%.

How Exogenous Sex Hormones Affect DEXA

Hormone Therapy in Postmenopausal Women

Estrogen therapy is the most effective non-bisphosphonate intervention for preserving bone in postmenopausal women. The Women's Health Initiative (WHI) randomized trial (N=16,608) found that conjugated equine estrogen plus medroxyprogesterone acetate reduced hip fracture risk by 33% (hazard ratio 0.67, 95% CI 0.47-0.96) compared to placebo over a mean 5.6-year follow-up (Rossouw et al., JAMA 2002). Estrogen-only therapy in hysterectomized women produced a similar 39% reduction in hip fractures (HR 0.61, 95% CI 0.41-0.91) in the estrogen-alone arm (Anderson et al., JAMA 2004). The 2022 Menopause Society (formerly NAMS) position statement supports initiating hormone therapy before age 60 or within 10 years of menopause specifically for bone preservation when the benefit-risk balance is favorable (The Menopause Society, Menopause 2022).

Testosterone Therapy in Men

In hypogonadal men, testosterone replacement therapy (TRT) increases lumbar spine BMD by approximately 5-8% over 12-24 months. The Testosterone Trials (TTrials) BONE sub-study (N=211 men, age 65 and older, testosterone <275 ng/dL) found that testosterone gel increased lumbar spine BMD by 7.5% and femoral neck BMD by 3.3% at 12 months versus placebo (P<0.001) (Snyder et al., JAMA Intern Med 2017). Volumetric BMD by quantitative CT improved even more, suggesting architectural as well as density gains.

Gender-Affirming Hormone Therapy

Transgender women (male-to-female, taking estrogen) gain BMD at the lumbar spine but may lose BMD at the hip if androgen suppression is pronounced and prior peak bone mass was suboptimal. A meta-analysis of 14 studies (N=392 transgender women) found a mean lumbar spine BMD Z-score improvement of 0.28 after 2 years of estrogen therapy (Singh-Ospina et al., Ann Intern Med 2017). Transgender men (female-to-male) on testosterone appear to maintain or modestly improve BMD, likely because testosterone aromatizes to estradiol in bone. Baseline DEXA before initiating gender-affirming therapy is recommended by the Endocrine Society (Hembree et al., JCEM 2017).

When to Order a DEXA Scan

Standard Screening Indications

The U.S. Preventive Services Task Force (USPSTF) recommends DEXA screening for all women aged 65 and older, and for postmenopausal women under 65 whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman with no additional risk factors (approximately 8.4% on FRAX) (USPSTF, JAMA 2018). The National Osteoporosis Foundation (NOF) extends this to all men aged 70 and older, and to men aged 50-69 with clinical risk factors (NOF Clinician's Guide 2014).

Earlier Screening Triggers

Order DEXA before standard age thresholds in the presence of any of the following: cumulative glucocorticoid use at 5 mg/day prednisone-equivalent for 3 or more months, primary hypogonadism or functional hypothalamic amenorrhea, anorexia nervosa, malabsorptive disorders (celiac disease, Crohn's), hyperparathyroidism, a prior fragility fracture, or use of aromatase inhibitors or androgen-deprivation therapy (Compston et al., Nat Rev Endocrinol 2019).

Premenopausal Considerations

Premenopausal women with regular cycles do not require routine DEXA absent risk factors. However, women with oligomenorrhea or amenorrhea lasting more than 6 months, those with a history of anorexia or RED-S, and those on long-term depot medroxyprogesterone acetate (which suppresses estrogen) benefit from early baseline scanning (Gordon et al., Pediatrics 2017).

FRAX Score and the Fracture Risk Calculation

BMD alone does not determine treatment. FRAX (Fracture Risk Assessment Tool), developed from 12 prospective cohorts, integrates T-score at the femoral neck with clinical risk factors to generate a 10-year probability of major osteoporotic fracture (MOF) and hip fracture. Inputs include age, sex, body mass index, prior fracture, parental hip fracture, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol consumption (Kanis et al., Osteoporos Int 2008).

The NOF treatment thresholds are: a 10-year hip fracture risk at or above 3%, or a 10-year MOF risk at or above 20%, or a T-score at or below -2.5 at any site, or a fragility fracture at any site (NOF Clinician's Guide 2014). FRAX can flag patients with T-scores in the osteopenic range (-1.0 to -2.5) who nevertheless carry sufficient clinical risk to justify pharmacotherapy.

Pharmacotherapy: Alendronate and Beyond

Alendronate as First-Line Therapy

Alendronate (70 mg oral once weekly or 10 mg once daily) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated resorption by binding hydroxyapatite and inducing osteoclast apoptosis. The Fracture Intervention Trial (FIT, N=6,459 postmenopausal women with low femoral neck BMD) showed that alendronate reduced vertebral fracture risk by 44% (relative risk 0.56, P<0.001) over 3 years and hip fracture risk by 51% in women with a baseline hip T-score at or below -2.5 (Cummings et al., JAMA 1998). The FDA approved alendronate for postmenopausal osteoporosis (FDA Label, alendronate sodium).

Oral Dosing Considerations

Alendronate must be taken with 6-8 ounces of plain water after an overnight fast, and the patient must remain upright for at least 30 minutes to minimize esophageal irritation. Weekly dosing produces the same BMD gain as daily dosing with better adherence in practice (Schnitzer et al., Aging Clin Exp Res 2000).

When to Consider Alternatives

Patients unable to tolerate oral bisphosphonates may use zoledronic acid 5 mg intravenously once yearly, which in the HORIZON Key Fracture Trial (N=7,765) reduced vertebral fractures by 70% and hip fractures by 41% over 3 years (Black et al., NEJM 2007). Denosumab (RANK-L inhibitor, 60 mg subcutaneously every 6 months) is preferred when renal impairment precludes bisphosphonates. Teriparatide and abaloparatide (anabolic agents) are reserved for severe osteoporosis or bisphosphonate failure.

Drug Holidays

After 5 years of oral bisphosphonate therapy in low-to-moderate risk patients, a drug holiday of 2-3 years is appropriate because bisphosphonates accumulate in bone mineral and continue to suppress resorption after cessation. High-risk patients (T-score below -2.5 or prior vertebral fracture) should not take drug holidays without specialist guidance (Black and Rosen, NEJM 2016).

Nutrition and Lifestyle Factors That Move the DEXA Number

Calcium and vitamin D are the foundation of any bone-health strategy but do not replace pharmacotherapy in established osteoporosis. The National Academy of Medicine recommends 1,000 mg elemental calcium per day for women aged 19-50 and men aged 19-70, rising to 1,200 mg for women 51 and older (NIH ODS Calcium Fact Sheet). Vitamin D sufficiency (serum 25-OH-D above 30 ng/mL) is required for intestinal calcium absorption; supplementation with 1,500-2,000 IU/day is adequate for most adults without malabsorption (Holick et al., JCEM 2011).

Resistance training and weight-bearing exercise each independently stimulate bone formation through mechanical loading. A meta-analysis of 17 RCTs (N=1,081 postmenopausal women) found that combined resistance plus impact exercise increased lumbar spine BMD by a weighted mean of 1.03% per year versus controls (Zhao et al., Osteoporos Int 2017). Smoking reduces BMD by 0.5-1 standard deviation at the hip in long-term smokers; alcohol consumption above 3 units per day is independently associated with a 1.38-fold increased hip fracture risk (Kanis et al., Osteoporos Int 2005).

Interpreting DEXA in the Context of Hormone Therapy Monitoring

A practical approach to DEXA in patients receiving hormone therapy follows this sequence. First, obtain a baseline scan before or within 6 months of initiating any hormone intervention that affects bone (estrogen, testosterone, aromatase inhibitor, GnRH agonist, depot progesterone). Second, calculate FRAX using the femoral neck T-score from that baseline. Third, repeat DEXA at 2 years if the patient is on pharmacotherapy to confirm an adequate response, defined as a stable or increasing BMD and no new fracture. Fourth, if bone turnover markers are used for interim monitoring, standardize the draw to mid-luteal phase in cycling women and to a consistent time of day (CTX is highest in the morning fasted state) across all patients.

The Endocrine Society clinical practice guideline on male hypogonadism specifies that DEXA should be obtained at baseline and after 1-2 years of TRT in men with osteoporosis or low bone mass, with the goal of confirming BMD stability or improvement (Bhasin et al., JCEM 2018). The Menopause Society similarly recommends DEXA at the initiation of hormone therapy and at 2-year intervals in women at elevated fracture risk (The Menopause Society, Menopause 2022).